1. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells
   Pauline Estupina et al, 2017, Oncotarget CrossRef
2. Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR
   Sarah E. Gill et al, 2017, Oncotarget CrossRef
3. The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages
   Houcine Bougherara et al, 2017, Oncotarget CrossRef
4. Anti-mullerian hormone receptor type II as a Potential Target for Antineoplastic Therapy
   A. Ya. Rak et al, 2019, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry CrossRef
5. Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II
   Cagri Sakalar et al, 2015, Journal of Immunology Research CrossRef
6. Interaction Study of Different Forms of Human Recombinant Anti-Mullerian Hormone with a Chimeric Analogue of the AMH Type II Receptor
   A. Ya. Rak et al, 2021, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry CrossRef
7. Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
   Suparna Mazumder et al, 2020, Oncotarget CrossRef
8. The role of anti-Mullerian hormone in the context of modern pathogenetic approaches to the treatment of endometriosis (literature review)
   N. A. Buralkina et al, 2023, Meditsinskiy sovet = Medical Council CrossRef